Literature DB >> 32822584

Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.

Frederic D Bushman1, Maire Conrad2, Yue Ren3, Chunyu Zhao4, Christopher Gu5, Christopher Petucci6, Min-Soo Kim6, Arwa Abbas7, Kevin J Downes8, Nina Devas4, Lisa M Mattei4, Jessica Breton2, Judith Kelsen2, Sarah Marakos4, Alissa Galgano4, Kelly Kachelries4, Jessi Erlichman4, Jessica L Hart9, Michael Moraskie4, Dorothy Kim4, Huanjia Zhang4, Casey E Hofstaedter4, Gary D Wu10, James D Lewis10, Joseph P Zackular7, Hongzhe Li3, Kyle Bittinger4, Robert Baldassano2.   

Abstract

Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infection with Clostridioides difficile (CDI). IBD and IBD + CDI have overlapping symptoms but respond to distinctive treatments, highlighting the need for diagnostic biomarkers. Here, we studied pediatric patients with IBD and IBD + CDI, comparing longitudinal data on the gut microbiome, metabolome, and other measures. The microbiome is dysbiotic and heterogeneous in both disease states, but the metabolome reveals disease-specific patterns. The IBD group shows increased concentrations of markers of inflammation and tissue damage compared with healthy controls, and metabolic changes associate with susceptibility to CDI. In IBD + CDI, we detect both metabolites associated with inflammation/tissue damage and fermentation products produced by C. difficile. The most discriminating metabolite found is isocaproyltaurine, a covalent conjugate of a distinctive C. difficile fermentation product (isocaproate) and an amino acid associated with tissue damage (taurine), which may be useful as a joint marker of the two disease processes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clostridioides difficile; Gram-positive; inflammatory bowel disease; isocaproate; isocaproyltaurine; metabolome; microbiome; taurine

Mesh:

Substances:

Year:  2020        PMID: 32822584      PMCID: PMC9332131          DOI: 10.1016/j.chom.2020.07.020

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   31.316


  79 in total

Review 1.  Plasmid and chromosome traffic control: how ParA and ParB drive partition.

Authors:  Jennifer A Surtees; Barbara E Funnell
Journal:  Curr Top Dev Biol       Date:  2003       Impact factor: 4.897

2.  Incidence of Clostridium difficile infection in inflammatory bowel disease.

Authors:  Joseph F Rodemann; Erik R Dubberke; Kimberly A Reske; Da Hea Seo; Christian D Stone
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

3.  Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.

Authors:  Abraham Goorhuis; Dennis Bakker; Jeroen Corver; Sylvia B Debast; Celine Harmanus; Daan W Notermans; Aldert A Bergwerff; Frido W Dekker; Ed J Kuijper
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

4.  Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid.

Authors:  Joseph A Sorg; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

Review 5.  Taurine and inflammatory diseases.

Authors:  Janusz Marcinkiewicz; Ewa Kontny
Journal:  Amino Acids       Date:  2012-07-19       Impact factor: 3.520

6.  Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids.

Authors:  Rajani Thanissery; Jenessa A Winston; Casey M Theriot
Journal:  Anaerobe       Date:  2017-03-06       Impact factor: 3.331

Review 7.  Microbe-microbe interactions during Clostridioides difficile infection.

Authors:  Arwa Abbas; Joseph P Zackular
Journal:  Curr Opin Microbiol       Date:  2020-02-20       Impact factor: 7.934

8.  Genetic manipulation of Clostridium difficile.

Authors:  Laurent Bouillaut; Shonna M McBride; Joseph A Sorg
Journal:  Curr Protoc Microbiol       Date:  2011-02

Review 9.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

10.  Sunbeam: an extensible pipeline for analyzing metagenomic sequencing experiments.

Authors:  Erik L Clarke; Louis J Taylor; Chunyu Zhao; Andrew Connell; Jung-Jin Lee; Bryton Fett; Frederic D Bushman; Kyle Bittinger
Journal:  Microbiome       Date:  2019-03-22       Impact factor: 14.650

View more
  15 in total

Review 1.  Omics in gut microbiome analysis.

Authors:  Tae Woong Whon; Na-Ri Shin; Joon Yong Kim; Seong Woon Roh
Journal:  J Microbiol       Date:  2021-02-23       Impact factor: 3.422

Review 2.  Computational approaches to understanding Clostridioides difficile metabolism and virulence.

Authors:  Matthew L Jenior; Jason A Papin
Journal:  Curr Opin Microbiol       Date:  2021-11-25       Impact factor: 7.934

3.  Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Caitlin W Elgarten; Ceylan Tanes; Jung-Jin Lee; Lara A Danziger-Isakov; Michael S Grimley; Michael Green; Marian G Michaels; Jessie L Barnum; Monica I Ardura; Jeffery J Auletta; Jesse Blumenstock; Alix E Seif; Kyle L Bittinger; Brian T Fisher
Journal:  Pediatr Blood Cancer       Date:  2021-10-28       Impact factor: 3.167

4.  Detection and elimination of a novel non-toxigenic Clostridioides difficile strain from the microbiota of a mouse colony.

Authors:  Jeffrey R Maslanka; Christopher H Gu; Isma Zarin; Joshua E Denny; Susan Broadaway; Bryton Fett; Lisa M Mattei; Seth T Walk; Michael C Abt
Journal:  Gut Microbes       Date:  2020-11-09

Review 5.  Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium.

Authors:  Amber D Reed; Casey M Theriot
Journal:  Microorganisms       Date:  2021-02-12

Review 6.  Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease.

Authors:  Cristina Bauset; Laura Gisbert-Ferrándiz; Jesús Cosín-Roger
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

Review 7.  Metabolomics facilitate the personalized management in inflammatory bowel disease.

Authors:  Rirong Chen; Jieqi Zheng; Li Li; Chao Li; Kang Chao; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

Review 8.  Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease.

Authors:  Yang Zheng; Yang Yu; Xu-Feng Chen; Sheng-Lan Yang; Xiao-Long Tang; Zheng-Guo Xiang
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

9.  Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Paul B Larkin; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2021-11-15       Impact factor: 5.325

10.  Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma.

Authors:  Máire A Conrad; Judith R Kelsen
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.